Stage II Breast Cancer AJCC v6 and v7
27
2
12
13
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 15/100
0.0%
0 terminated out of 27 trials
100.0%
+13.5% vs benchmark
11%
3 trials in Phase 3/4
77%
10 of 13 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 13 completed trials
Clinical Trials (27)
Phase I Trial of Endoxifen Gel Versus Placebo in Women Undergoing Breast Surgery
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer
Radiation Therapy in Treating Patients With Stage 0-II Breast Cancer
Electroacupuncture Therapy in Reducing Chronic Pain in Patients After Breast Cancer Treatment
Carboplatin and Paclitaxel With or Without Atezolizumab Before Surgery in Treating Patients With Newly Diagnosed, Stage II-III Triple-Negative Breast Cancer
Cyclophosphamide, Paclitaxel, and Trastuzumab in Treating Stage I-II HER2/Neu Positive Breast Cancer After Surgery
Hypofractionated Radiation Therapy or Standard Radiation Therapy in Treating Patients With Ductal Breast Carcinoma In Situ or Early Invasive Breast Cancer
Multicenter Trial for Eliminating Breast Cancer Surgery or Radiotherapy in Exceptional Responders to Neoadjuvant Systemic Therapy
Hypofractionated Partial Breast Irradiation in Treating Patients With Early Stage Breast Cancer
Patient Reported Outcomes, Smart Pill Bottle and Teleheath for Endocrine Therapy Adherence
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Hypofractionated vs. Conventional Regional Nodal Radiation Therapy for Patients With Invasive Breast Cancer
The Role of Lifestyle Factors in Breast Cancer-Related Outcomes
Women's MoonShot: Neoadjuvant Treatment With PaCT for Patients With Locally Advanced TNBC
Molecular Testing and Imaging in Improving Response in Patients With Stage I-III Triple-Negative Breast Cancer Receiving Chemotherapy MDACC Breast Moonshot Initiative
Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib
Enzalutamide and Paclitaxel Before Surgery in Treating Patients With Stage I-III Androgen Receptor-Positive Triple-Negative Breast Cancer
Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery
TPIV100 and Sargramostim for the Treatment of HER2 Positive, Stage II-III Breast Cancer in Patients With Residual Disease After Chemotherapy and Surgery
Alternative Dosing of Exemestane Before Surgery in Treating Postmenopausal Patients With Stage 0-II Estrogen Positive Breast Cancer